Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Lung Cancer
•
Thoracic Malignancies
•
Medical Oncology
•
NCI-CCC Tumor Board Question
•
Ohio State University
•
General Internal Medicine
•
NCI-CCC Thoracic Tumor Board Question
How would you manage grade 3 treatment-emergent diabetes mellitus (HbA1c of 11.1, anti-GAD65) in a patient with ES-SCLC on atezolizumab maintenance?
Related Questions
In ES-SCLC presenting with extensive brain metastases, how do you time whole brain radiation after the first cycle of chemotherapy has already been delivered?
In light of the 2024 Shkreli Awards, how do you address patient concerns regarding the 240 mg versus 960 mg dose of sotorasib?
What are the main practical factors to consider when using bispecific antibody therapy (Tarlatamab) for extensive-stage small cell lung cancer?
When will you choose Tarlatamab over an alternative systemic therapy (e.g. lurbinectedin, topotecan) for relapsed ES SCLC?
In stage IV oligometastatic NSCLC, when considering local consolidative therapies to the primary tumor, do providers typically stage the mediastinum at diagnosis or after initial systemic therapy (assuming no progression)?
What is the role of surveillance imaging after first line therapy in patients with aggressive lymphomas?
What are your top takeaways in Thoracic Cancers from ASCO 2025?
Does receipt of chemoimmunotherapy for LS-SCLC impact your recommendation for PCI?
Can Dupixent and Durvalumab be used at the same time in a patient with extensive stage small cell lung cancer?
Given potential long-term CV toxicity concerns with lorlatinib and data suggesting that dose reduction does not compromise efficacy, do you ever recommend initiating and/or maintaining lower-dose lorlatinib in ALK+ NSCLC?
